

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number  
WO 2004/089372 A1

(51) International Patent Classification<sup>7</sup>: A61K 31/454,  
31/506, A61P 25/22, 25/24

(74) Common Representative: JANSSEN PHARMACEU-  
TICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).

(21) International Application Number:  
PCT/EP2004/050492

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(22) International Filing Date: 8 April 2004 (08.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PCT/EP03/03879 11 April 2003 (11.04.2003) EP

(71) Applicant (for all designated States except US):  
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turn-  
houtseweg 30, B-2340 Beerse (BE).

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): STECKLER,  
Thomas, Horst, Wolfgang [DE/BE]; c/o Janssen Phar-  
maceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).  
JANSSENS, Frans, Eduard [BE/BE]; c/o Janssen  
Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse  
(BE). LEENAERTS, Joseph, Elisabeth [BE/BE]; c/o  
Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340  
Beerse (BE). FERNÁNDEZ-GADEA, Francisco, Javier  
[ES/ES]; c/o Janssen Cilag S.A., Edificio Johnson &  
Johnson, Paseo de las Doce Estrellas, 5-7, Campo de las  
Naciones, E-28042 Madrid (ES). GÓMEZ-SÁNCHEZ,  
Antonio [ES/ES]; c/o Janssen Cilag S.A., Edificio Johnson  
& Johnson, Paseo de las Doce Estrellas, 5-7, Campo de las  
Naciones, E-28042 Madrid (ES). MEERT, Theo, Frans  
[BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg  
30, B-2340 Beerse (BE).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,  
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD,  
SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,

[Continued on next page]

(54) Title: SUBSTITUTED 4-PHENYL-4-[1H-IMIDAZOL-2-YL]-1-PIPERIDINE DERIVATIVES AND THEIR USE AS SELEC-  
TIVE NON-PEPTIDE DELTA OPIOID AGONISTS WITH ANTIDEPRESSANT AND ANXIOLYTIC ACTIVITY



(I)

(57) Abstract: The present invention relates to the  
use of 4-phenyl-4-[1H-imidazol-2-yl]-piperidine  
derivatives according to Formula (I) the  
pharmaceutically acceptable acid or base addition  
salts thereof, the stereochemically isomeric forms  
thereof, the tautomeric forms thereof and the  
N-oxide forms thereof as selective non-peptide  
δ-opioid agonists for use in the prevention and/or  
treatment of various central nervous system  
disorders, in particular as selective antidepressant  
and anxiolytic non-peptide δ-opioid agonists. In  
particular are claimed compounds according to  
Formula (I) in which A=B is C=O or SO<sub>2</sub>, X is a  
covalent bond, R<sup>1</sup> is alkyloxy, alkyloxyalkyl, Ar or  
zero, R<sup>2</sup> is benzyl optionally substituted with hydroxy, alkyl or alkyloxycarbonyl and R<sup>4</sup> and R<sup>5</sup> each are hydrogen.

NR<sup>9</sup>R<sup>10</sup>, wherein R<sup>9</sup> and R<sup>10</sup> each independently are hydrogen or Ar; or A=B and R<sup>1</sup> together form a benzoxazolyl radical; p is  
zero, R<sup>2</sup> is benzyl optionally substituted with hydroxy, alkyl or alkyloxycarbonyl and R<sup>4</sup> and R<sup>5</sup> each are hydrogen.

WO 2004/089372 A1



CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT,  
LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,  
TD, TG)

- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report

- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.